CORONAVIRUS UPDATE   

UK Confirmed Cases: 409,729   |   UK Deaths: 41,862   |   UK New Cases: 6,178   |   UK New Deaths: 37   |   Italy Confirmed Cases: 302,537   |   Italy Deaths: 35,758   |   Italy New Cases: 1,640   |   Italy New Deaths: 20   |   France Confirmed Cases: 483,956   |   France Deaths: 31,459   |   France New Cases: 9,784   |   France New Deaths: 46   |   Spain Confirmed Cases: 693,556   |   Spain Deaths: 31,034   |   Spain New Cases: 11,289   |   Spain New Deaths: 130   |   Germany Confirmed Cases: 279,205   |   Germany Deaths: 9,508   |   Germany New Cases: 2,029   |   Germany New Deaths: 17   |   USA Confirmed Cases: 7,136,877   |   USA Deaths: 206,527   |   USA New Cases: 38,940   |   USA New Deaths: 1,046   |  

Last updated: 24 Sep 2020, 17:00 GMT  

Coronavirus Live:    Latest News & Updates

Russia has issued a registration certificate for a new Covid19 vaccine. The certification is somewhat restrictive since the vaccine can only be administered to a limited number of people, at this time. The vaccine is only available to those who have been classified as vulnerable, elderly patients and medical staff.
The certification stipulates that the vaccine cannot be administered to the general public until January 1st 2021.
So have the Russians won the global vaccine race? Well in truth it’s too early to tell, but in spite of the almost universal criticism among international medical academics and scepticism from virologists and epidemiologists Sputnik 5 has been in the works in one form or another for at least 3 to 5 years.
However the main concern is that Sputnik 5 has been certified without completing the crucial Phase lll trails, which is the ultimate litmus test for side-effects and immune system responses. Russia has not made any scientific reports and studies available so far in spite of repeatedly assurances that studies will be available for peer review by International virologists and scientists.
Only with the passage of time can a real verdict be reached. Russia has certainly cut corners, but if health and safety guidelines have been adhered to maybe a world pandemic of this magnitude calls for expediting the usual trial procedures in order to avoid other more dangerous consequences.

27,595,422 Total numbers of confirmed cases.
7,114,925 Total numbers of active cases.
898,622 Total number of reported deaths.
60,338 Total number of critical cases.
19,466,818 Total number of patients who have recovered.
There are 170 potential vaccines and antibody treatments in various stages of development around the world. Best case scenario suggests that a vaccine will be available somewhere in the last quarter of 2020.
The front runners are the UK’s Oxford University/AstraZeneca ChAdOx1 nCov-19 vaccine which running neck and neck with Moderna Therapeutics. mRNA-1237 Both Vaccines are now in Phase lll trials.
Moderna’s trial will include some 30,000 participants in the US, which put the US challenger slightly ahead of the Oxford’s vaccine However, Oxford’s Phase lll trials includes a major trial in Brazil which could tilt the race in favour of ChAdOx1 nCov-19.

The oxford University team that is leading the global vaccine race against Covid19 has reached a breakthrough in the development of an antibody treatment targeted to the elderly and the particularly vulnerable.
The treatment involves injecting a patient with a combination of two cloned antibodies which allows the body to counteract Covid19. The treatment is especially effective for those in the early stages of infection.
In a further positive development, AstraZeneca in announcing the breakthrough reported that the Serum Institute of India is considering funding the antibody treatment as a stand alone project.

The World Health Organization (WHO) estimates that countries that do not have a reliable electricity supply and cannot maintain an effective cold-chain delivery system account for more than 1.5 million deaths globally, because vaccines for treatable diseases are rendered useless on arrival.
The University of Birmingham and Herriot-Watt University in Edinburgh with collaboration from leading international institutions have initiated a Covid-19 related investigation into finding the most efficient way to distribute future covid vaccines, which may be temperature sensitive, on a global scale.
Universal vaccines access has been a major concern affecting millions of people in low income countries especially where refrigeration logistics are sparse at best. The latest statistics from the Global Alliance for Vaccines and Immunization suggests that less then 10% of the healthcare centres in poorer counties have a reliable supply of electricity let alone adequate vaccine-qualified refrigerators.
The challenge to effectuate rapid mass immunisation and create a reliable and sustainable cold-chain logistics system offers a unique opportunity to solve the problems that continue to plague universal vaccines access.
One approach that is being considered is creating community cooling hubs which could help meet the different communities’ cooling needs in a clean, affordable and sustainable way while helping to safeguard people’s health.
Professor Phil Greening, from Herriot-Watt University, explained “… a vaccine is one of the very few exit strategies around which scientists and government are aligned. …. (and) we need a global effort to prepare the vaccine and in parallel a global strategy to develop the appropriate sustainable and legacy equitable cold chains and achieve this with minimum environmental impact.

A COVID-19 symptom tracker has been developed by Kings College London and Zoe Global, a health science company. The tracker has been endorsed by the Welsh and Scottish governments as well as NHS Wales and NHS Scotland. There are currently just under three million users who are reporting via the App.
The purpose of the App is to track the progress of the virus from its inception through to its ultimate termination. As more and more users provide daily reports on their condition, the data which is analysed by a dedicated scientific team, is creating a much more accurate picture of how the virus starts , how quickly it spreads and how it attacks the lungs.
The data has also demonstrated that Covid-19 is disproportionately more prevalent and more aggressive in people living in urban areas and locations of higher poverty.
The data is also highlighting those who are most susceptible to the virus and those for whom Covid-19 is most likely to be fatal.
This data is critical to scientists and healthcare policy makers in monitoring the pandemic, guiding resources to critical hot spots and developing more accurate modelling predictions.
To date there are 2,963,429 self-reporting contributors.
If you have Covid-19 symptoms or are recovering from the virus download the App and help to contain the pandemic.

The government has pulled out all the stops by setting up the world’s largest randomised clinical trials of potential drugs to tackle the COVID-19 virus at a speed which is unheard of in clinical trials.
The UK has taken the lead on research in the race to find a cure for Covid-19 by pooling resources from across the country from its world renowned healthcare centres of excellence
Recovery Trial, as the project has been called, recruited over 5,000 patients within a month in 165 NHS hospitals, well ahead of the US and Europe, with the hope of finding some positive solutions within weeks.
The medicines being tested include:-
Hydoxychloroquine a drug that has been around for some 65 years and is used to treat Malaria.
Dexamethasone a steroid used to reduce inflammation.
Lopinavir-Ritonavir a drug used in the treatment of HIV.
Recovery Trial is being coordinated by researchers at Oxford University led by Peter Horby, professor of emerging infectious diseases and global health and Martin Landray, Professor of Medicine and Epidemology.
This bold decisive action by the government means that potential Covid-19 treatments could be available to NHS patients as soon as they prove effective. This kind of speed is unprecedented.

Latest Alerts

Sonovia, an Israeli start-up, has developed a reusable anti-viral fabric face mask which should be able to neutralize 99% of the Covid19 virus.
Unlike a regular disposable mask the SonoMask provides dual and durable protection both for the wearer and for those in close contact with the wearer.
The mask which can be washed multiple times is coated in zinc oxide nano particles that destroy bacteria, fungi and viruses. Most importantly it provides an effective shield for the wearer from contracting the virus.
The fabric which can be used in textiles for hospitals, PPE, and clothing is awaiting certification for use by medical professionals in emergency rooms and operating theatres.
In May of this year the fabric was tested at the Austria’s HygCen medical lab using the Vaccinia virus which is almost identical to the SARS-Covid virus. That test showed, “a good virucidal effect “according to the lab report.
Further tests have been conducted in the microspectrum, Weipu Jishu laboratory in China and an additional test is being carried out in Beijing, with a report due within the next few days.
If, as expected the results show a 99% efficacy, Sonovia will be partnering with strategic manufacturers around the world to create a full range of protective equipment including respirators and hazard suits.

On Saturday August 1st the US Food and Drug Administration granted an Emergency Use Authorization to SalivaDirect a saliva test procedure developed by Yale’s School of Public Health, to detect Covid19. This authorization followed a major trial involving asymptomatic players, coaches and staff of the US National Basketball Association. This is the 5th Covid 19 test approved by the FDA.
In describing the efficacy of this test, the terms “groundbreaking” and a “game change” were used to heap praise on the latest entry of the Covid-Identity-kit sweepstakes. There are however, a number of valid reasons to suggest that this new devise may indeed stand out from the pack.
The test requires no swabs or collection devices it just uses spit from those being tested. Furthermore it does not rely on expensive, hard to source chemical components to test the saliva. As Professor Nathan Grubaugh explained,” once we established that the virus was stable in saliva for a prolonged period of time at a warm temperatures, we dispensed with the need for preservatives, special test tubes and we sourced the least expensive reagent for the analysis.
SalivaDirecrt is simple, fast and equally as accurate as the gold standard swab tests which have a 90% accuracy rating with a turn around time within 24 hours. However, it has been designed to test people who are asymptomatic not for hospital patients. So its ideal for Schools, business and medical institutions to get students back to school, healthcare workers back to hospitals and employees back to work.
SalivaDirect can be used two or three times a week on staff, students and healthcare workers and the cost is around £6 per test. Introducing the test could increase daily testing by up to 200,000 tests a day.

Professor Eli Schwartz, who heads the Centre for Travel Medicine and Tropical Disease at Sheba Medical Centre, Tel Hashomer, Israel, has launched a clinical trial of the drug Ivermectin. The drug is a broad-spectrum and parasitic agent that is used to fight parasites in third-world countries has shown some positive indications in fighting viruses in general and could help “cure” COVID-19. Professor Schwartz shied away from the anti-malaria based drugs focusing instead on drugs which demonstrate strong antiviral activities and Ivermectin seemed to fit the bill. Clinical trials are now underway to determine if Ivermectin, administered to non-hospital patients with moderate cases, can reduce the viral shedding period which would allow them to test negative for the virus and leave isolation in just a few days.
To date the Professor’s team have been able to record viral clearance within six days post-intervention. If this can be established at the conclusion of the trials then Ivermectin will prove to be much more effective then Remdesivir.
Although Professor Schwartz is not looking specifically on Ivermectin ability to reduce mortality, preliminary results of a US study of Ivermectin involving patients with severe symptoms showed that it may reduce mortality.
The results of the US study was bolstered by an Australian research project which found that Ivermectin was capable of killing COVID-19 within 48 hours in a cell culture.

The antimicrobial elements found in copper, which has been well established over the past 60 years and is now, finally, receiving intense interest among the so called international scientific community because has the potential of killing SARS-Cov-2 the new strain of CaronaVirus that causes the Covid19 infections.
More importantly given copper’s aggressive antiviral activities, we thought that it should be essential for healthcare professionals to know how they can advise patients to ingest copper as a primary weapon in preventing becoming infested. This information we believe is critical because Copper is an essential trace mineral that cannot be formed by the human body. It must be ingested from dietary sources.
In that vain we include below a list of foods that one should eat in order to ingest copper, it’s a list of healthy foods and its broad enough to include meat lovers and ardent vegans:-
The best dietary sources are seafood (especially shellfish), organ meats (e.g., liver), whole grains, legumes (e.g., beans and lentils) and chocolate.
Nuts, including peanuts and pecans, are especially rich in copper, as are grains like wheat and rye, and fruits including lemons and raisins.
Other food sources include cereals, potatoes, peas, red meat, mushrooms, some dark green leafy vegetables like kale, and fruits like coconuts, papaya, and apples. Tea, rice and chicken are relatively low in copper, but can provide a reasonable amount of copper when they are consumed in significant amounts.
Eating a balanced diet with a range of foods from different food groups is the best way to avoid copper deficiency. In both developed and developing countries, adults, young children, and adolescents who consume diets of grain, millet, tuber, or rice along with legumes (beans) or small amounts of fish or meat, some fruits and vegetables, and some vegetable oil are likely to obtain adequate copper if their total food consumption is adequate in calories.
We hope this list affords our members an opportunity to for members to revise their daily diets and we in turn will offer more supplementary advice as we receive it from the experts.

In 2008 the world’s largest study of hospital surfaces made up of copper materials proved conclusively that the anti-microbial properties in copper destroyed killer bacteria and stopped the spread of infections through touch and finger-tip contamination. (Selly Oak Hospital, Birmingham).
The study headed up by Professor Tom Elliott found that copper taps, toilet seats, door push plates, door handles, handrails, switches, hospital carts and so on, all but eliminated infectious micro-organisms that existed.
Lab tests showed that copper kills off MRSA, C difficle superbugs and a range of other dangerous germs including flu virus and the E coli food poisoning bug. Addionally a study led by Professor Peter Lambert at Aston University, Birmingham showed the efficacy of copper when patients were treated in rooms where touch surfaces were copperized, compared to patients treated in regular rooms. The infection rates of the patients in the copperized rooms were reduced by 48% .
In spite of the overwhelming evidence that replacing stainless steel in key touch areas with copper, not one hospital made any significant changes. Five years later York Health Economics Consortium designed a business model that showed that projects for installing anti-microbial copper touch surfaces in just IC Units would pay for themselves in less then a year.
This study was recently underscored by a US study which showed that the direct cost of treating a single patient with a hospital-acquired infection is approximately $45,000 whereas 70% of hospital-acquired infections could be eliminated by rooms being refitted with copper replacements in key touch areas at a cost of $5000.
The anti-microbial activities of copper are effective against Covid19 and immediate steps should be taken to replace key touch areas in hospitals, schools, public buildings in order to stop the spread of the coronavirus.
Using copper is as critical as washing hands, sanitisation, social distancing and wearing face masks.

NHS Staff Offers
CLICK HERE for FULL List

Morrisons are offering all NHS heroes a 10% discount on grocery shopping. The offer is valid till 30th September.

WHSmiths in-hospital stores have increased the discounts on offer to 20% on all food and drinks.

AA Rescue. If you work for the NHS and you break down travelling between home and work, call AA 24/7 on your dedicated NHS number 0800 072 5064. Show your NHS ID to the patrol when they arrive – no requirement to be an AA member.

Deliveroo has 50,000 £20 vouchers available for NHS staff. NHS workers can redeem their £20 voucher by setting up a Deliveroo account with their NHS email address.

and Many, Many More….






Secondary Care Members

Primary Care Members